Ixaka and Minaris Regenerative Medicine sign tech transfer, manufacturing agreement for cell therapy candidate REX-001
Ixaka, an integrated cell and gene therapy company, and Minaris Regenerative Medicine, a leading contract development and manufacturing service provider for the cell and gene therapy industry, have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001, Ixaka’s lead autologous multi-cell therapy (MCT) being developed for the treatment […]
